Positive topline data for resminostat in RESMAIN pivotal study demonstrating 97.6% improvement in progression free survival in CTCL patients and risk reduction of 38% compared to placebo Marketing Authorization Application for resminostat and nominated trade name of Kinselby accepted by EMA Kinselby uniquely positioned as maintenance treatment for CTCL Cash runway to Q3 2024 Planegg-Martinsried, […]